AMNEAL PHARMACEUTICALS, INC. Selling, General and Administrative Expense
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Selling, General and Administrative Expense of $148.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $148.72M, a 19.68% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $138.86M, a 17.39% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $146.46M, a 13.81% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $137.81M, a 16.11% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $526.83M, a 10.58% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $476.44M, a 10.88% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $429.68M, a 7.50% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $399.70M, a 9.36% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $148.72M 10-Q · filed 2026-08-06 | $287.58M 10-Q · filed 2026-08-06 | $434.04M derived: sum of 3 quarters · filed 2026-08-06 | $571.86M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $138.86M 10-Q · filed 2026-05-07 | $285.32M derived: sum of 2 quarters · filed 2026-05-07 | $423.13M derived: sum of 3 quarters · filed 2026-05-07 | $547.40M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $146.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $284.27M derived: sum of 2 quarters · filed 2026-02-27 | $408.54M derived: sum of 3 quarters · filed 2026-08-06 | $526.83M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $137.81M 10-Q · filed 2025-11-06 | $262.08M derived: sum of 2 quarters · filed 2026-08-06 | $380.37M 10-Q · filed 2025-11-06 | $509.06M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $124.27M 10-Q · filed 2026-08-06 | $242.55M 10-Q · filed 2026-08-06 | $371.24M derived: sum of 3 quarters · filed 2026-08-06 | $489.93M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $118.29M 10-Q · filed 2026-05-07 | $246.97M derived: sum of 2 quarters · filed 2026-05-07 | $365.67M derived: sum of 3 quarters · filed 2026-05-07 | $482.13M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $128.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $247.38M derived: sum of 2 quarters · filed 2026-02-27 | $363.84M derived: sum of 3 quarters · filed 2026-02-27 | $476.44M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $118.69M 10-Q · filed 2025-11-06 | $235.15M derived: sum of 2 quarters · filed 2025-11-06 | $347.75M 10-Q · filed 2025-11-06 | $456.75M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $116.46M 10-Q · filed 2025-08-07 | $229.06M 10-Q · filed 2025-08-07 | $338.06M derived: sum of 3 quarters · filed 2026-02-27 | $451.07M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $112.59M 10-Q · filed 2025-05-07 | $221.60M derived: sum of 2 quarters · filed 2026-02-27 | $334.60M derived: sum of 3 quarters · filed 2026-02-27 | $440.17M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $109.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $222.01M derived: sum of 2 quarters · filed 2026-02-27 | $327.58M derived: sum of 3 quarters · filed 2026-02-27 | $429.68M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $113.01M 10-Q · filed 2024-11-12 | $218.58M derived: sum of 2 quarters · filed 2024-11-12 | $320.67M 10-Q · filed 2024-11-12 | $422.83M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-06-30 | $105.57M 10-Q · filed 2024-08-09 | $207.67M 10-Q · filed 2024-08-09 | $309.82M derived: sum of 3 quarters · filed 2025-02-28 | $409.89M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-03-31 | $102.10M 10-Q · filed 2024-05-08 | $204.25M derived: sum of 2 quarters · filed 2025-02-28 | $304.32M derived: sum of 3 quarters · filed 2025-02-28 | $403.13M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $102.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $202.23M derived: sum of 2 quarters · filed 2025-02-28 | $301.04M derived: sum of 3 quarters · filed 2025-02-28 | $399.70M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $100.07M 10-Q · filed 2023-11-09 | $198.88M derived: sum of 2 quarters · filed 2023-11-09 | $297.54M 10-Q · filed 2023-11-09 | $394.77M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | $98.81M 10-Q · filed 2023-08-08 | $197.47M 10-Q · filed 2023-08-08 | $294.69M derived: sum of 3 quarters · filed 2024-03-14 | $386.09M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | $98.67M 10-Q · filed 2023-05-09 | $195.89M derived: sum of 2 quarters · filed 2024-03-14 | $287.29M derived: sum of 3 quarters · filed 2024-03-14 | $373.44M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | $97.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $188.62M derived: sum of 2 quarters · filed 2024-03-14 | $274.78M derived: sum of 3 quarters · filed 2024-03-14 | $365.50M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | $91.40M 10-Q · filed 2022-11-07 | $177.55M derived: sum of 2 quarters · filed 2022-11-07 | $268.28M 10-Q · filed 2022-11-07 | $352.97M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | $86.16M 10-Q · filed 2022-08-08 | $176.88M 10-Q · filed 2022-08-08 | $261.57M derived: sum of 3 quarters · filed 2023-03-03 | $344.69M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | $90.73M 10-Q · filed 2022-05-06 | $175.41M derived: sum of 2 quarters · filed 2023-03-03 | $258.53M derived: sum of 3 quarters · filed 2023-03-03 | $339.48M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | $84.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $167.81M derived: sum of 2 quarters · filed 2023-03-03 | $248.75M derived: sum of 3 quarters · filed 2023-03-03 | $326.73M 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | $83.12M 10-Q · filed 2021-11-08 | $164.06M derived: sum of 2 quarters · filed 2021-11-08 | $242.04M 10-Q · filed 2021-11-08 | $316.12M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $80.94M 10-Q · filed 2021-08-09 | $158.92M 10-Q · filed 2021-08-09 | $233.00M derived: sum of 3 quarters · filed 2022-03-01 | $296.80M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $77.98M 10-Q · filed 2021-05-07 | $152.06M derived: sum of 2 quarters · filed 2022-03-01 | $215.86M derived: sum of 3 quarters · filed 2022-03-01 | $283.14M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $74.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $137.88M derived: sum of 2 quarters · filed 2022-03-01 | $205.16M derived: sum of 3 quarters · filed 2022-03-01 | $289.60M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $63.80M 10-Q · filed 2020-11-06 | $131.08M derived: sum of 2 quarters · filed 2020-11-06 | $215.51M 10-Q · filed 2020-11-06 | $286.75M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $67.28M 10-Q · filed 2020-08-06 | $151.72M 10-Q · filed 2020-08-06 | $222.95M derived: sum of 3 quarters · filed 2021-03-01 | $298.44M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $84.44M 10-Q · filed 2020-05-11 | $155.67M derived: sum of 2 quarters · filed 2021-03-01 | $231.16M derived: sum of 3 quarters · filed 2021-03-01 | $287.16M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $71.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $146.72M derived: sum of 2 quarters · filed 2021-03-01 | $202.72M derived: sum of 3 quarters · filed 2021-03-01 | $227.85M 10-K · filed 2021-03-01 | $230.44M 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $75.49M 10-Q · filed 2019-11-07 | $78.08M 10-Q · filed 2018-11-07 | $131.49M derived: sum of 2 quarters · filed 2019-11-07 | $156.61M 10-Q · filed 2019-11-07 | $156.20M 10-Q · filed 2018-11-07 | $183.58M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $56.00M 10-Q · filed 2019-08-05 | $53.00M 10-Q · filed 2018-08-09 | $81.12M 10-Q · filed 2019-08-05 | $78.12M 10-Q · filed 2018-08-09 | $108.09M derived: sum of 3 quarters · filed 2020-03-02 | $135.53M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $25.12M 10-Q · filed 2019-05-09 | $52.09M derived: sum of 2 quarters · filed 2020-03-02 | $79.53M derived: sum of 3 quarters · filed 2020-03-02 | $106.47M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $26.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $54.41M derived: sum of 2 quarters · filed 2020-03-02 | $81.34M derived: sum of 3 quarters · filed 2020-03-02 | $109.05M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $27.44M 10-Q · filed 2018-11-07 | $54.38M derived: sum of 2 quarters · filed 2018-11-07 | $82.08M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $26.94M 10-Q · filed 2018-08-09 | $54.64M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | $118.76M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |